secwatch.observer — SEC 8-K summary
======================================

Issuer:     Passage BIO, Inc. (PASG)
CIK:        0001787297
Form:       8-K
Filed at:   2024-09-16T23:59:59+00:00
Accession:  0001558370-24-012793
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PBFT02 shows robust CSF progranulin increase; well-tolerated with enhanced immunosuppression
--------------------------------------------------------------------------------

- CSF PGRN up to 6-fold at month 1 (10.7-17.3 ng/mL) and up to 10-fold at month 6 (21.7-27.3 ng/mL), exceeding healthy controls (3.3-8.2 ng/mL).
- No serious adverse events in patients 2-5 with enhanced immunosuppression; first patient had SAEs with lower steroid regimen.
- CSF PGRN remained elevated at 12 months (34.2 ng/mL), with rate of increase slowing from 58% to 26% between months 1-6 and 6-12.
- Cohort 2 currently enrolling; Cohort 4 anticipated to open in first half of 2025 for FTD-C9orf72.
- Plasma PGRN expression remained below healthy reference levels across all five patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787297/000155837024012793/0001558370-24-012793-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787297/000155837024012793/pasg-20240916x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-012793

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer